Abstract
COVID-19, caused by the novel coronavirus SARS-CoV-2, has spread globally and caused serious social and economic problems. The WHO has declared this outbreak a pandemic. Currently, there are no approved vaccines or antiviral drugs that prevent SARS-CoV-2 infection. Drugs already approved for clinical use would be ideal candidates for rapid development as COVID-19 treatments. In this work, we screened 1,473 FDA-approved drugs to identify inhibitors of SARS-CoV-2 infection using cell-based assays. The antiviral activity of each compound was measured based on the immunofluorescent staining of infected cells using anti-dsRNA antibody. Twenty-nine drugs among those tested showed antiviral activity against SARS-CoV-2. We report this new list of inhibitors to quickly provide basic information for consideration in developing potential therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 1843-1853 |
| Number of pages | 11 |
| Journal | Journal of Microbiology and Biotechnology |
| Volume | 30 |
| Issue number | 12 |
| DOIs | |
| State | Published - 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- COVID-19
- FDA-approved drugs
- Repurposing screens
- SARS-CoV-2
Fingerprint
Dive into the research topics of 'Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver